142 related articles for article (PubMed ID: 35517883)
1. High Sensitivity Troponin T as Complementary Modality for Determining Doxorubicin Regimen Cardiotoxicity in Non-Hodgkin Lymphoma Patients.
Prayogo AA; Suryantoro SD; Savitri M; Hendrata WM; Wijaya AY; Pikir BS
Adv Pharm Bull; 2022 Jan; 12(1):163-168. PubMed ID: 35517883
[No Abstract] [Full Text] [Related]
2. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
[TBL] [Abstract][Full Text] [Related]
3. 3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin's lymphoma.
Mihalcea D; Florescu M; Bruja R; Patrascu N; Vladareanu AM; Vinereanu D
Sci Rep; 2020 Oct; 10(1):18473. PubMed ID: 33116212
[TBL] [Abstract][Full Text] [Related]
4. Myocardial work-A new tool for early detection of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy induced-cardiotoxicity in hematological patients.
Mihalcea D; Memis H; Balinisteanu A; Vladareanu AM; Mihaila S; Vinereanu D
J Clin Ultrasound; 2023 Mar; 51(3):377-384. PubMed ID: 36331055
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
6. [Early detection of the cardiotoxicity induced by chemotherapy drug through two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T].
Wang W; Kang Y; Shu XH; Shen XD; He B
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):835-840. PubMed ID: 29151290
[No Abstract] [Full Text] [Related]
7. A Novel Predictor of Chemotherapeutic Cardiotoxicity in Patients with Non-Hodgkin Lymphoma.
Gurdogan M; Ozkan U
Oncol Res Treat; 2019; 42(7-8):375-381. PubMed ID: 31132772
[TBL] [Abstract][Full Text] [Related]
8. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
Kang Y; Xu X; Cheng L; Li L; Sun M; Chen H; Pan C; Shu X
Eur J Heart Fail; 2014 Mar; 16(3):300-8. PubMed ID: 24464946
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.
Limat S; Daguindau E; Cahn JY; Nerich V; Brion A; Perrin S; Woronoff-Lemsi MC; Deconinck E
J Clin Pharm Ther; 2014 Apr; 39(2):168-74. PubMed ID: 24384030
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single-center, retrospective observational study.
Nakayama T; Oshima Y; Kusumoto S; Yamamoto J; Osaga S; Fujinami H; Kikuchi T; Suzuki T; Totani H; Kinoshita S; Narita T; Ito A; Ri M; Komatsu H; Wakami K; Goto T; Sugiura T; Seo Y; Ohte N; Iida S
EJHaem; 2020 Nov; 1(2):498-506. PubMed ID: 35845008
[TBL] [Abstract][Full Text] [Related]
11. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma.
Limat S; Demesmay K; Voillat L; Bernard Y; Deconinck E; Brion A; Sabbah A; Woronoff-Lemsi MC; Cahn JY
Ann Oncol; 2003 Feb; 14(2):277-81. PubMed ID: 12562656
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
13. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
14. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.
Sancho JM; Fernández-Alvarez R; Gual-Capllonch F; González-García E; Grande C; Gutiérrez N; Peñarrubia MJ; Batlle-López A; González-Barca E; Guinea JM; Gimeno E; Peñalver FJ; Fuertes M; Bastos M; Hernández-Rivas JÁ; Moraleda JM; García O; Sorigué M; Martin A
Cancer Med; 2021 Feb; 10(4):1314-1326. PubMed ID: 33492774
[TBL] [Abstract][Full Text] [Related]
15. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D
Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730
[TBL] [Abstract][Full Text] [Related]
16. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Nousiainen T; Jantunen E; Vanninen E; Hartikainen J
Br J Cancer; 2002 Jun; 86(11):1697-700. PubMed ID: 12087452
[TBL] [Abstract][Full Text] [Related]
17. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
Kilickap S; Yavuz B; Aksoy S; Sahiner L; Dincer M; Harputluoglu H; Erman M; Aytemir K; Tokgozoglu L; Barista I
Med Oncol; 2008; 25(4):437-42. PubMed ID: 18415035
[TBL] [Abstract][Full Text] [Related]
18. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
20. B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin for Risk Stratification in Low-Flow, Low-Gradient Aortic Stenosis: A Substudy of the TOPAS Study.
Dahou A; Clavel MA; Capoulade R; O'Connor K; Ribeiro HB; Côté N; Le Ven F; Rodés-Cabau J; Dumesnil JG; Mathieu P; Pibarot P
JACC Cardiovasc Imaging; 2018 Jul; 11(7):939-947. PubMed ID: 28917673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
